BioNTech stock rises 15% within 3 months of Makary's departure

Makary's exit signals potential regulatory easing for biotech firms, particularly mRNA vaccine developers like BioNTech. A more favorable FDA stance could accelerate approval timelines for pipeline candidates, boosting investor confidence.

Implied probability (Yes)

60%